INCB001158 Combined With Subcutaneous (SC) Daratumumab Compared to Daratumumab SC in Relapsed or Refractory Multiple Myeloma

  • STATUS
    Recruiting
  • days left to enroll
    41
  • participants needed
    98
  • sponsor
    Incyte Corporation
Updated on 7 July 2021

Summary

The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma.

Details
Condition Relapsed or Refractory Multiple Myeloma
Treatment Daratumumab SC, INCB001158
Clinical Study IdentifierNCT03837509
SponsorIncyte Corporation
Last Modified on7 July 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note